XML 25 R61.htm IDEA: XBRL DOCUMENT v2.4.0.6
Acquisitions, License and Research Agreements (Details) (DuoCort Pharma AB)
In Millions, unless otherwise specified
1 Months Ended
Nov. 30, 2011
USD ($)
item
Nov. 30, 2011
SEK
item
Nov. 30, 2011
Milestones
Maximum
USD ($)
Nov. 30, 2011
Milestones
Maximum
SEK
Nov. 30, 2011
Milestones
Minimum
USD ($)
Nov. 30, 2011
Milestones
Minimum
SEK
Nov. 30, 2011
Specific Regulatory Milestones
Maximum
USD ($)
Nov. 30, 2011
Specific Regulatory Milestones
Maximum
SEK
Nov. 30, 2011
Commercial Milestones
Maximum
USD ($)
Nov. 30, 2011
Commercial Milestones
Maximum
SEK
Business acquisition                    
Ownership interest (as a percent) 100.00% 100.00%                
Upfront cash payment of acquisition $ 32.1 213.0                
Contingent consideration, potential cash payment     132 860 37 240 25 160 107 700
Number of components of contingent consideration payments 3 3                
Transaction cost incurred on acquisition $ 1.4